Background:
Pericarditis, inflammation of the pericardium, is the most prevalent pericardial disease and a prominent cause of acute chest discomfort in young people (1). It is mostly caused by viral infections as well as rheumatic illnesses, uremia, or neoplasms (2). A pericardial friction rub, concave ST-segment elevations, pleuritic chest discomfort, and pericardial effusion are all common indications and symptoms (1). Given that pericarditis is generally self-limited, the therapy is usually supportive, including nonsteroidal anti-inflammatory medications or colchicine. Other causes of pericarditis, on the other hand, may have different prognosis and therapeutic implications (3, 4).
Up to 15% over all acute myocardial infarction (AMI) patients and 25% of individuals with anterior myocardial infarction suffer from a left ventricular thrombus (LVT) (5, 6). With the introduction of early percutaneous coronary intervention (PCI) as a widely used treatment of AMI, the incidence of LVT decreased dramatically. LVT is most typically seen in patients with late-onset MI in clinical practice. It is infrequently seen in patients who report early and receive fast revascularization, especially in the first 24 hours after an AMI (7).
Coronavirus Disease 2019 (COVID-19) has grown significantly in scale as a result of the development of the novel Zoonotic Severe Acute Respiratory Syndrome Coronavirus-2. In addition to the predominance of respiratory symptoms, cardiovascular problems have also been reported(8).
A COVID-19 patient with ST elevation MI and LV thrombus with signs and symptoms of pericarditis was introduced.